For the complete documentation index, see llms.txt. This page is also available as Markdown.
FDA Pharmaceutical Pilot: Proving Blockchain for Drug Traceability
The Challenge: The U.S. Drug Supply Chain Security Act (DSCSA) mandates unit-level track and traceability for pharmaceuticals. Traditional EDI systems handle document exchange but can't verify product authenticity or provide rapid traceability during recalls. Counterfeit drugs cost the pharmaceutical industry billions annually and threaten patient safety.
The Solution: In 2019, the FDA launched a landmark pilot with IBM, KPMG, Merck, and Walmart to test blockchain's viability for meeting DSCSA interoperability requirements. The collaboration connected disparate existing systems—manufacturer, distributor/dispenser, and technology providers—to create a common record of product movement while preserving EDI for routine transactions.
The Results:
Dramatic improvement in patient safety capabilities: Proved drug provenance could be accurately captured on blockchain
Data privacy maintained: "One up, one down" permissioned view protected sensitive information
Verified authenticity: Every pharmaceutical unit tracked from manufacturing through delivery
EDI preserved: Existing document exchange systems continued operating normally
Published findings: February 2020 final report confirmed successful proof of concept
